Landmark 14 · Discovery

Extra copies of the synuclein gene cause Parkinson's

In short

Simply having too much normal alpha-synuclein is enough to cause Parkinson's, the main reason for trying to lower it.

What it is
Discovery
Outcome
Confirmed and built on
When
2003
Approach
Clear the bad protein
Research lane
Synuclein lowering
Last checked
19 Oct 2026

The research record

This is the project's file for this landmark, as written and checked. Sources are listed at the end; anything not yet confirmed is marked "Not yet verified".

Who

Andrew Singleton (National Institute on Aging, Bethesda), Matthew Farrer, John Hardy, Katrina Gwinn-Hardy and 18 co-authors (22 in all). Funders were not checked.

What happened

In a large family (the Iowa kindred, named in the authors' later clinical report) with dominantly inherited Parkinson's and no SNCA point mutation, linkage mapping placed the disease region on chromosome 4 around SNCA. Quantitative PCR and FISH showed the region is triplicated (about 2 Mbp, 17 genes), and the extra gene dose was judged the most likely explanation. Science 302:841, 31 October 2003. In 2004 two papers in The Lancet found whole-gene duplications (two copies instead of three) in families with a milder, more typical Parkinson's: one French family (Chartier-Harlin et al.) and two patients (Ibáñez et al.), showing a dose effect. This differs from landmark 4, where a changed protein caused disease; here the protein is normal but there is too much of it.

Why it moved us toward a cure

It is the main rationale for lowering alpha-synuclein by any route: antisense drugs, antibodies or other methods.

Outcome

Advanced. Synuclein-lowering strategies are in trials, but none has shown a clinical benefit yet.

Sources

How it connects

Built on

Led to

See it on the research map

Report an error on this page

Back to top